Elite in Pheochromocytoma

David Taieb

264 Rue Saint Pierre, 
Marseille, FR 
Elite in Pheochromocytoma
264 Rue Saint Pierre, 
Marseille, FR 
OverviewLocationsClinical Research

Overview

David Taieb practices in Marseille, France. Mr. Taieb is rated as an Elite expert by MediFind in the treatment of Pheochromocytoma. His top areas of expertise are Pheochromocytoma, Neuroendocrine Tumor, Adrenal Cancer, Parathyroidectomy, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 284 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 85 articles in the study of Pheochromocytoma.

Gender
Male

Locations

264 Rue Saint Pierre, Marseille, 13385, France
Other Locations
Aix-en-provence, France
CLCC Antoine Lacassagne
Nice, France
Hospices Civils de Lyon
Lyon, France
Paris, France
Site Constitutif, 125, Rue De Stalingrad, Bobigny, 93000, France
2, Avenue Foch, Brest, 29609, France
264, Rue Saint Pierre, Saint-pierre-les-bois, 13385, France
264, Rue Saint Pierre, Marseille 05, 13385, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors
Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors
Enrollment Status: Completed
Publish Date: April 06, 2023
Intervention Type: Other
Study Phase: Not Applicable
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Other
Study Phase: Not Applicable
View 1 Less Clinical Trial

284 Total Publications

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Taieb's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile